|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
HUMAN PROTEOME PROJECT | ||||||||||||||||
December 06, 2000 | ||||||||||||||||
Cambridge Healthtech Institute, McLean, Virginia April 2-4, 2001 Without doubt the Human Genome Project has taken several giant steps into the twenty-first century, both for science and for self-knowledge. As its fruits fall into our hands, it is important to acknowledge the remarkable efforts and insights that made this happen. We should also note that despite this outstanding success, many new questions have concomitantly emerged. Beneath this new gestalt, we now face a more complicated view of ourselves. Logically, on this incremental path to self-advancement, we now confront the Proteome. Our main goal is to actuate public and private energies to fuse into a single panoply. Consensual and careful planning at the outset will harness the naturally occurring forces of politics and markets, technology and pure research. Underscoring the sine qua non status of cooperation, round-table discussions are planned in plenary session. These will be moderated by respected independent figures. The politics of inclusion will be front and center at all times. |
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Dr. Stanley Abramowitz, National Institute of Standards and Technology Dr. Norman G. Anderson, Large Scale Biology Corporation Dr. Paul Bardel, Myriad Genetics, Inc. Dr. Franklin Berger, JP Morgan Securities Inc. Dr. Allan Bombard, Aetna U.S. Healthcare Dr. Marvin Cassman, National Institute of General Medical Science Dr. Julio Celis, Danish Centre for Human Genome Research Dr. Jasemine Chambers, U.S. Patent and Trademark Office Dr. Christopher Earl, Perseus LLC Dr. Christine Ethier, Genomic Solutions, Inc. Dr. James I. Garrels, Proteome, Inc. Dr. John Hefti, Signature BioScience, Inc. Dr. Ian Humphery-Smith, University of Utrecht and Glaucus Proteomics B.V. Dr. Trey Ideker, The Institute for Systems Biology Dr. Stephen Kingsmore, Molecular Staging Dr. Joshua LaBaer, Harvard Medical School Dr. Lance Liotta, National Cancer Institute Dr. Matthias Mann, Protana A/S Dr. Ralph McDade, Luminex Corporation Dr. Michael P. McKenna, CuraGen Corporation Dr. Raj Parekh, Oxford GlycoSciences Dr. Ari Patrinos, U.S. Department of Energy Dr. Dale Patterson, Perceptive Biosystems, Inc. Dr. Emanuel Petricoin III, U.S. Food and Drug Administration Mr. Antonio Regalado, Wall Street Journal Dr. Monica Riley, Woods Hole Oceanographic Institute Dr. Peter Roepstorff, Odense University Dr. Ajay Royyuru, T. J. Watson IBM Research Center Dr. Richard D. Smith, Pacific Northwest National Laboratory Dr. Subramanyam Swaminathan, Brookhaven National Laboratory Mr. John E. Tarcza, Large Scale Proteomics Corporation Dr. Brad Walsh, Macquarie University Dr. John Wiktorowicz, Lynx Therapeutics, Inc. |
|||||||||||||||
Deadline for Abstracts: | March 2, 2001 | |||||||||||||||
Registration: | Available on-line | |||||||||||||||
E-mail: | jlaakso@healthtech.com | |||||||||||||||
Posted by: | Jennifer Laakso | |||||||||||||||
Host: | wks217.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |